Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. DiNardo on the FDA Approval of Oral Azacitidine in AML

September 1st 2020

Courtney DiNardo, MD, MSCE, discusses the FDA approval of oral azacitidine (CC-486) in acute myeloid leukemia (AML).

Venetoclax Plus Azacitidine Significantly Prolongs OS, Incidence of Remission in AML

September 1st 2020

Venetoclax plus azacitidine led to a statistically significant prolongation of overall survival with a higher incidence of remission in treatment-naïve older patients with acute myeloid leukemia.

Addressing Diagnostic Challenges in HSCT-TMA and Exploring Emerging Biomarkers

August 31st 2020

Biomarkers predictive of risk in hematopoietic stem cell transplantation–associated thrombotic microangiopathy have undergone a recent evolution, with several new markers under exploration and many efforts focused on making current markers more precise and accurate to strengthen diagnostic criteria.

Dr. Lai on the Potential Benefits of Venetoclax in AML

August 31st 2020

Catherine Lai, MD, MPH, discusses the potential benefits of venetoclax in acute myeloid leukemia.

Emerging Evidence Supports the Use of Narsoplimab in HSCT-TMA

August 31st 2020

Rafael F. Duarte, MD, PhD, FRCP, presents 2 real-world clinical cases in which the investigational monoclonal antibody narsoplimab demonstrated clinical benefit in patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Leveraging the Lectin Pathway in Endothelial Injury Syndromes

August 31st 2020

Eleni Gavriilaki, MD, PhD, discusses the rationale for the lectin pathway as a therapeutic target in hematopoietic stem cell transplantation–associated thrombotic microangiopathy.

Dr. Richter on the Utility of Isatuximab in Relapsed/Refractory Myeloma

August 31st 2020

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

Hill Highlights the Potential of Selinexor as a Less Intensive Option for DLBCL

August 31st 2020

Brian T. Hill, MD, PhD, sheds light on XPO1 as a target in diffuse large B-cell lymphoma, the emergence of selinexor in the treatment landscape, and exciting agents in the pipeline.

Daratumumab Plus CyBorD Poised to Change Frontline AL Amyloidosis Care

August 30th 2020

Sandy Wong, MD, discusses the ANDROMEDA trial, the need for further investigation of venetoclax, and research with anti-amyloid fibril drugs in light chain amyloidosis.

Dr. Dimopoulos on the Goal of the ASPEN Trial in Waldenström Macroglobulinemia

August 29th 2020

Meletios A. Dimopoulos, MD, discusses the goal of the phase 3 ASPEN trial in Waldenström macroglobulinemia.

Dr. Daver on the Tolerability of Magrolimab Plus Azacitidine in AML/MDS

August 29th 2020

Naval G. Daver, MD, discusses the tolerability of magrolimab plus azacitidine in patients with acute myeloid leukemia and myelodysplastic syndrome.

Dr. Verstovsek on the MANIFEST Trial With CPI-0610 in Myelofibrosis

August 29th 2020

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

Emerging Approaches Seek to Expand the Relapsed/Refractory Follicular Lymphoma Treatment Arsenal

August 28th 2020

Lori A. Leslie discusses several key studies evaluating emerging approaches in the relapsed/refractory follicular lymphoma paradigm.

CAR T-Cell Therapies Continue to Raise the Bar in Lymphoma Management

August 27th 2020

Pashna N. Munshi, MD, discusses the CAR T-cell therapies that have emerged in the lymphoma space and highlights the next steps for research with these products.

Enzastaurin Combo Under Exploration in High-Risk, DGM1+ DLBCL

August 27th 2020

Investigators are evaluating the efficacy of enzastaurin, a PCKß inhibitor, in combination with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with high-risk DGM1–positive diffuse large B-cell lymphoma.

Asciminib Elicits Significant Major Molecular Responses in Ph+ Chronic-Phase CML

August 26th 2020

The novel investigational STAMP inhibitor asciminib significantly improved the major molecular response rate compared with bosutinib at 24 weeks in adult patients with Philadelphia chromosome–positive, chronic-phase chronic myeloid leukemia who received prior treatment with 2 or more TKIs.

Enasidenib Plus Best Supportive Care Misses OS End Point in Relapsed/Refractory IDH2+ AML

August 25th 2020

Enasidenib in combination with best supportive care failed to significantly improve overall survival in patients with relapsed/refractory acute myeloid leukemia whose tumors harbor an IDH2 mutation.

NCCN Guidelines Grant Tafasitamab Category 2A Designation in DLBCL

August 21st 2020

Tafasitamab has been added to the Clinical Practice Guidelines in Oncology by the National Comprehensive Cancer Network for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.

CLR 131 Leads to 100% Response Rate Among Patients With Relapsed/Refractory B-Cell Malignancies

August 21st 2020

The novel phospholipid-drug conjugate CLR 131 induced a 100% overall response rate in patients with relapsed/refractory lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

Dr. Chari on Investigational Belantamab Mafodotin Combos in Myeloma

August 20th 2020

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.